Sachs Associates’ Post

FluoSphera is a patent-protected technology platform developing a unique set of disruptive technologies mimicking the clinical response to drugs under systemic conditions to accurately predict drug safety and efficacy. Such high-throughput systemic assays reliably identify the most promising lead compounds early during drug discovery to decrease drug development failure in the clinic, thus increasing the chance for the patients to get access to the best therapeutics while reducing animal experimentation. Meet FluoSphera @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Could a game-changing solution to the treatment of solid tumors and autoimmune diseases be on the horizon? A fascinating new article from UKT news dives into the remarkable possibilities of T-Cypher Bio's D-Cypher, an integrated platform that could potentially revolutionize the biotech industry. This Oxford-based startup are planning to overcome the challenges met with current therapeutics, as they push the boundaries of science to transform lives. Don't miss out on this enlightening read: https://UKT.news/?p=10417 #Biotech #HealthcareInnovation #TCRBiotherapeutics #DCypher #OxfordStartup

Atlas Venture 𝐡𝐚𝐬 𝐮𝐧𝐯𝐞𝐢𝐥𝐞𝐝 Diagonal Therapeutics, 𝐚 𝐂𝐚𝐦𝐛𝐫𝐢𝐝𝐠𝐞-𝐛𝐚𝐬𝐞𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐬𝐭𝐚𝐫𝐭𝐮𝐩 𝐭𝐡𝐚𝐭 𝐡𝐚𝐬 𝐫𝐚𝐢𝐬𝐞𝐝 $𝟏𝟐𝟖 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐭𝐨 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐭𝐡𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐨𝐟 𝐚𝐠𝐨𝐧𝐢𝐬𝐭 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐫𝐚𝐫𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬. Key Highlights: ▪ Diagonal Therapeutics’ innovative platform combines computational and experimental techniques to optimize the binding interactions between receptors and agonist antibodies, addressing a long-standing challenge in the field ▪ The company's lead program targets hereditary hemorrhagic telangiectasia (HHT), a severe bleeding disorder with limited treatment options, by activating the genetically impaired receptor in HHT patients. ▪ Diagonal's pipeline also includes programs targeting pulmonary arterial hypertension (PAH) and solid tumors, leveraging the potential of agonist antibodies to tackle the underlying causes of these diseases. ▪ With the $128 million Series A funding led by BVF Partners and Atlas, Diagonal aims to advance its HHT program through clinical proof-of-concept and further develop its pipeline. Don't miss out on tracking such groundbreaking initiatives in detail through our comprehensive market research reports focused on antibody therapeutics: https://lnkd.in/gGnRd-2b #RareDisease #AntibodyTherapies #AntibodyTherapeutics #Biotech #Innovation #SeriesA #AntibodyMarket #Funding #MarketInsights #TechnologyTrends #DrugDevelopment #Therapeutics #LifeSciences #HealthTech #BiotechStartup

Learn more about the standard in AAV manufacturing with our latest article

The April 2024 Advanced Therapies issue of BioProcess International is available in print and digital! This issue features fascinating articles from talented professionals. Read on for a preview of the articles linked below: Derisking the Road to Commercially Viable Stem-Cell Therapies by Ricardo Baptista, Stijn Heessen, Kristian Tryggvason, & Thomas Hope. The Evolution of Medicine: Empowering Healthcare for the Delivery of Advanced Therapies by Rohin I. & Robert Brackner. A Milestone in Macrophage-Based Cancer Treatment: Leveraging Chimeric Antigen Receptors To Address Solid Tumors by Brian Gazaille & Michael Klichinsky. Regenerative Medicine for Cardiovascular Disease: Characterization and Clinical Success by Ibon Garitaonandia, PhD, MBA. Microfluidic Cell Sorting: Scaling for Clinical and Therapeutic Applications by Nicholas Tan Kwan Zen, Jongyoon Han, & Kerwin Kwek Zeming. Characterization of Hydrogel Carriers: Improving the Efficacy of Existing Cell Therapies by Stella K. Vnook, Megan Hamilton, PhD, & Lisa Stehno-Bittel. Rev Up AAV Genome Production by Rebecca Reese, PhD, Jennifer Swanson, Austin Storck, & Laura Juckem. Setting the Standard in Cell- and Gene-Therapy Manufacturing: Tackling Performance, Scalability, and Regulatory Compliance Challenges Together by Prity Bengani-Lutz, Lorraine Borland, Paul C., David Ede, Katy McLaughlin, & Marc Noverraz. Biologics Manufacturing from Gene to Product by Dr. Thilo Kamphausen & Kai Pohlmeyer. Leveraging dPCR Techniques To Analyze Lentivirus Particles (Webcast Summary) by Samyuktha (Samy) Shankar. The Unrecognized Role of Mixing During Tangential-Flow Filtration (Webcast Summary) by Lucas Smith. CAR-T Therapy Manufacturing: Lessons from the Automotive Industry by Josh Ludwig. #advancedtherapies #cellandgenetherapies #celltherapy #genetherapy Follow the link below to read the full issue now. https://lnkd.in/gGkugQcA

BIG pharma invests $500m in CGT this week, 𝗛𝗲𝗿𝗲'𝘀 𝟯 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 👇 1. 𝐕𝐞𝐫𝐭𝐞𝐱 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 and 𝐓𝐫𝐞𝐞𝐅𝐫𝐨𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 have announced a collaboration to enhance the production of cell therapies for 𝐭𝐲𝐩𝐞 1 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 . Vertex has acquired an exclusive license to TreeFrog's C-StemTM technology, aiming to optimise the manufacturing process for T1D therapies. 2. 𝐁𝐌𝐒 and 𝐂𝐞𝐥𝐥𝐚𝐫𝐞𝐬 have entered a $380million agreement for the manufacturing of CAR T cell therapies, aiming to expand access to these therapies for patients. BMS will utilise 𝐂𝐞𝐥𝐥𝐚𝐫𝐞𝐬' 𝐂𝐞𝐥𝐥 𝐒𝐡𝐮𝐭𝐭𝐥𝐞, an advanced automated manufacturing platform, for clinical and commercial-scale production of specific CAR T cell therapies 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒., 𝐄𝐔, 𝐚𝐧𝐝 𝐉𝐚𝐩𝐚𝐧. 3. 𝐋𝐞𝐱𝐞𝐨 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 has secured IP rights from Cornell University, following years of partnership aimed at advancing its gene therapy LX2006 for Friedreich ataxia cardiomyopathy. This therapy targets mitochondrial function and is a significant step in advancing their clinical progress. #celltherapy #genetherapy #biotech #CGTweekly

🔬 Exciting Publication -->Apricell Biotechnology -->3-in-1 Plate! 🔬 Researchers utilized the 3D #tumoroid culture plate from Apricell Biotechnology Inc. to create a human-mimicked #Glioblastoma tumor model. This study aimed to evaluate the impact of #localized combination #drugdelivery on the #viability and invasive behavior of tumor #spheroids within a bio-mimicked #extracellularmatrix of the tumor site. https://lnkd.in/e74gjkcA 💡At Apricell Biotechnology Inc., we are committed to advancing scientific innovation and revolutionizing the way researchers conduct cell-based assays. 3-in-1 Plate offers a cutting-edge solution for creating physiologically relevant #3dcellculture models, facilitating #therapeutic screening, and accelerating #drugdiscovery efforts. We are proud to contribute to advancing cancer research and look forward to seeing the impact of our 3-in-1 plate on the future of #invitro human-mimicked #cancer models. For more information on our revolutionary range of products, including the 3-in-1 Plate, please visit our website or contact us directly at info@apricell.com. Let us work together to explore new possibilities in 3D cell culture and therapeutic discovery! #Microfluidics #organoids #DrugDiscovery #BiomedicalResearch #Innovation #Science #Publication #ResearchAdvancement

🌟 Join Us for the Donor Selection and Cell Source Summit! 🌟 The cell therapy field is at the forefront of a revolution, especially in developing treatments for autoimmune patients. With over 150+ clinical trials currently underway and recent FDA approvals for allogeneic cell products, the momentum in this space is undeniable. 🚀 As the allogeneic cell therapy field continues to mature, the focus is now shifting to one of the most critical aspects of these therapies—the cell donors. We’re excited to announce that this year's summit will address the core questions and challenges surrounding donor characterization, with a special emphasis on: 🔍 Donor Variability 🎯 Donor Selection 🔄 Donor Retention / Consistent Donor Supply 📈 Scalability / Safety & Efficacy We've collaborated with leading companies in the Cell Therapy space, including Sana Biotech, Poseida Therapeutics, and BMS, to craft an agenda that will propel this emerging field even further. Don't miss out on this opportunity to be part of the conversation that's shaping the future of cell therapy! #CellTherapy #DonorSelection #AllogeneicTherapy #Biotech #HealthcareInnovation The full agenda can be viewed here: https://lnkd.in/eJRRzzhU

Unveiling Growth Opportunities in the Global #OrphanDrug Industry ⚕️ Amidst the landscape of #rarediseases, the quest for innovative treatments intensifies, fueled by a convergence of advancements in #precisionmedicine, #informatics, and #oncology. Frost & Sullivan's latest analysis uncovers how emerging technologies like precision oncology and gene-editing techniques are reshaping the orphan drug (OD) industry. 🔗Dive into our comprehensive perspectives to seize the #growthopportunities in this dynamic sector 👉https://hubs.la/Q02sxhyW0 Robin Joffe | Nitin Naik | Nimisha Iyer | Arun Stanly | Abdulaziz Jalab | Hani Al Sayed | Reenita Das | Sherin George